© The Author 2006. Published by Oxford University Press.
COMMENTARY |
Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations
Affiliations of authors: Division of Cancer Epidemiology and Genetics (LBT, CSR, LMB, BPA, NC, SC, MH, PI, RK, NR, MAT, MHG), Center for Cancer Research (WDF), National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD; University of York, York, UK (JMA); Department of Epidemiology, Roswell Park Cancer Institute, Buffalo, NY (CBA); Memorial Sloan-Kettering Cancer Center, New York, NY (CBB, KO); University of Pennsylvania, Philadelphia (AD); The Princess Margaret Hospital, University of Toronto, Ontario, Canada (MKG); Center for Radiological Research, Columbia University, New York, NY (EJH); Laboratory of Radiobiology, Harvard School of Public Health, Boston, MA (JBL); The Hospital for Sick Children, Toronto, Ontario, Canada (DM); Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute (AKN), Boston, MA; St. Jude Children's Research Hospital, Memphis, TN (C-HP); University of Minnesota, Minneapolis (LLR); Lombardi Cancer Center, Washington, DC (PGS); University of Texas M. D. Anderson Cancer Center, Houston (LS); Fred Hutchinson Cancer Research Center, Seattle, WA (TT)
Correspondence to: Lois B. Travis, MD, Division of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, National Cancer Institute, 6120 Executive Blvd., EPS # 7086, MSC 7238, Bethesda, MD 20892 (e-mail: travisl{at}mail.nih.gov).
Cancer survivors constitute 3.5% of the United States population, but second primary malignancies among this high-risk group now account for 16% of all cancer incidence. Although few data currently exist regarding the molecular mechanisms for second primary cancers and other late outcomes after cancer treatment, the careful measurement and documentation of potentially carcinogenic treatments (chemotherapy and radiotherapy) provide a unique platform for in vivo research on gene–environment interactions in human carcinogenesis. We review research priorities identified during a National Cancer Institute (NCI)–sponsored workshop entitled "Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers." These priorities include 1) development of a national research infrastructure for studies of cancer survivorship; 2) creation of a coordinated system for biospecimen collection; 3) development of new technology, bioinformatics, and biomarkers; 4) design of new epidemiologic methods; and 5) development of evidence-based clinical practice guidelines. Many of the infrastructure resources and design strategies that would facilitate research in this area also provide a foundation for the study of other important nonneoplastic late effects of treatment and psychosocial concerns among cancer survivors. These research areas warrant high priority to promote NCI's goal of eliminating pain and suffering related to cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. A. Jacobs, S. C. Palmer, L. A. Schwartz, A. DeMichele, J. J. Mao, J. Carver, C. Gracia, C. E. Hill-Kayser, J. M. Metz, M. K. Hampshire, et al. Adult Cancer Survivorship: Evolution, Research, and Planning Care CA Cancer J Clin, November 1, 2009; 59(6): 391 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Mayne and S. B. Gruber Emerging Molecular Technologies for Identifying the Risk of Second Cancers Cancer Prevention Research, July 1, 2009; 2(7): 605 - 607. [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Tsimberidou, S. Wen, P. McLaughlin, S. O'Brien, W. G. Wierda, S. Lerner, S. Strom, E. J Freireich, L. J. Medeiros, H. M. Kantarjian, et al. Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma J. Clin. Oncol., February 20, 2009; 27(6): 904 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Figueiredo, A. J. Levine, M. V. Grau, E. L. Barry, P. M. Ueland, D. J. Ahnen, T. Byers, R. S. Bresalier, R. W. Summers, J. Bond, et al. Colorectal Adenomas in a Randomized Folate Trial: The Role of Baseline Dietary and Circulating Folate Levels Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2625 - 2631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hemminki, P. Lenner, J. Sundquist, and J. Lorenzo Bermejo Risk of Subsequent Solid Tumors After Non-Hodgkin's Lymphoma: Effect of Diagnostic Age and Time Since Diagnosis J. Clin. Oncol., April 10, 2008; 26(11): 1850 - 1857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L J Worrillow, A G Smith, K Scott, M Andersson, A J Ashcroft, G M Dores, B Glimelius, E Holowaty, G H Jackson, G L Jones, et al. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma J. Med. Genet., March 1, 2008; 45(3): 142 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis Multiple Primary Cancers: An Overview of the National Cancer Institute's Surveillance, Epidemiology, and End Results Program ASCO Educational Book, January 1, 2008; 2008(1): 413 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Fossa Second Cancers among Survivors of Testicular Cancer: The Emerging Picture ASCO Educational Book, January 1, 2008; 2008(1): 423 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Demark-Wahnefried, E. C. Clipp, I. M. Lipkus, D. Lobach, D. C. Snyder, R. Sloane, B. Peterson, J. M. Macri, C. L. Rock, C. M. McBride, et al. Main Outcomes of the FRESH START Trial: A Sequentially Tailored, Diet and Exercise Mailed Print Intervention Among Breast and Prostate Cancer Survivors J. Clin. Oncol., July 1, 2007; 25(19): 2709 - 2718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Hodgson, E. S. Gilbert, G. M. Dores, S. J. Schonfeld, C. F. Lynch, H. Storm, P. Hall, F. Langmark, E. Pukkala, M. Andersson, et al. Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma J. Clin. Oncol., April 20, 2007; 25(12): 1489 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Fossa, E. Gilbert, G. M. Dores, J. Chen, K. A. McGlynn, S. Schonfeld, H. Storm, P. Hall, E. Holowaty, A. Andersen, et al. Noncancer Causes of Death in Survivors of Testicular Cancer J Natl Cancer Inst, April 4, 2007; 99(7): 533 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis Evaluation of the Risk of Therapy-Associated Complications in Survivors of Hodgkin Lymphoma Hematology, January 1, 2007; 2007(1): 192 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cardinale, A. Colombo, M. T. Sandri, G. Lamantia, N. Colombo, M. Civelli, G. Martinelli, F. Veglia, C. Fiorentini, and C. M. Cipolla Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition Circulation, December 5, 2006; 114(23): 2474 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schottenfeld and J. Beebe-Dimmer Alleviating the Burden of Cancer: A Perspective on Advances, Challenges, and Future Directions. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2049 - 2055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Travis The Epidemiology of Second Primary Cancers Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2020 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Mayne and B. Cartmel Chemoprevention of Second Cancers Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2033 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Rowland and R. Yancik Cancer survivorship: the interface of aging, comorbidity, and quality care. J Natl Cancer Inst, April 19, 2006; 98(8): 504 - 505. [Full Text] [PDF]
|
|
|
|
|
|
M. K. Gospodarowicz and R. M. Meyer The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 253 - 258. [Abstract] [Full Text] [PDF]
|
|